Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
ISIN : US09062X1037
Total Employee Number:
7,500Compare
Compare
Traded in other countries / regions
BIIB.USABIIB.Argentina0R1B.UKIDP.GermanyBIIB34.BrazilBIIB.Mexico1BIIB.ItalyBIIB.AustriaBIIB_KZ.KazakhstanBIIB.SwitzerlandBIIB.Chile Index Membership
S&P 500Russell 1000Russell 3000MSCI World IndexNASDAQ 100 IPO Date
1991-09-17Description
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.44 | |||||
Debt-to-EBITDA | 3.91 | |||||
Interest Coverage | 6.79 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.92 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.2 | |||||
3-Year EBITDA Growth Rate | -16 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | 19.6 | |||||
3-Year Book Growth Rate | 10.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.13 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.32 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.7 | |||||
9-Day RSI | 57.82 | |||||
14-Day RSI | 56.76 | |||||
3-1 Month Momentum % | 6.47 | |||||
6-1 Month Momentum % | 4.12 | |||||
12-1 Month Momentum % | 43.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.87 | |||||
Quick Ratio | 1.26 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 307.51 | |||||
Days Sales Outstanding | 72.72 | |||||
Days Payable | 56.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | -1.25 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74 | |||||
Operating Margin % | 19.29 | |||||
Net Margin % | 8.32 | |||||
EBITDA Margin % | 21.33 | |||||
FCF Margin % | 24.83 | |||||
OCF Margin % | 28.71 | |||||
ROE % | 4.56 | |||||
ROA % | 2.81 | |||||
ROIC % | 6.75 | |||||
3-Year ROIIC % | -6.64 | |||||
ROC (Joel Greenblatt) % | 24 | |||||
ROCE % | 4.92 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 38.37 | |||||
Forward PE Ratio | 17.48 | |||||
PE Ratio without NRI | 15.52 | |||||
Shiller PE Ratio | 10.99 | |||||
Price-to-Owner-Earnings | 20.98 | |||||
PS Ratio | 3.22 | |||||
PB Ratio | 1.7 | |||||
Price-to-Free-Cash-Flow | 12.87 | |||||
Price-to-Operating-Cash-Flow | 11.14 | |||||
EV-to-EBIT | 30.17 | |||||
EV-to-Forward-EBIT | 20.37 | |||||
EV-to-EBITDA | 18.28 | |||||
EV-to-Forward-EBITDA | 14.23 | |||||
EV-to-Revenue | 3.9 | |||||
EV-to-Forward-Revenue | 3.72 | |||||
EV-to-FCF | 15.7 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Projected-FCF | 0.9 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
Earnings Yield (Greenblatt) % | 3.31 | |||||
FCF Yield % | 7.77 | |||||
Forward Rate of Return (Yacktman) % | -0.68 |
Biogen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biogen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-05 08:30 | In 169 days | ||
| Annual report for 2026 | 2027-02-05 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-05 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 70 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 205.61 (+2.29%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 205.61 (+2.29%) | ||
| General meeting for 2026 | 2026-06-09 09:00 | 192.62 (-2.71%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 183.38 (+0.51%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 183.38 (+0.51%) |
Show
Entries
Press Release
Articles on Biogen Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers